Lentiviral Gene Therapies Market Size, Share & Industry Analysis, By Product (Skysona, Lyfgenia, Zynteglo, Libmeldy, and Others), By Delivery Method (Ex-vivo and In-vivo), By Disease Indication (Β-Thalassemia, Cerebral Adrenoleukodystrophy (CALD), Metachromatic Leukodystrophy (MLD), Sickle Cell Disease, and Others), By End User (Hospitals & Clinics, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global lentiviral gene therapies market size was valued at USD 240.0 million and is projected to reach USD 1,450.0 million by 2032, exhibiting a CAGR of 24.5% during the forecast period.

The market is projected to grow exponentially over the upcoming years due to rapid advancements in vector technologies and gene editing tools. Lentiviral gene therapies offer various advantages over traditional gene therapy vectors such as lower immunogenicity and stable long-term gene expression. Moreover, improved scalability of vector manufacturing and rising collaborations between biopharmaceutical companies and CDMOs are strengthening the supply chain to bridge the gap and meet clinical needs. Collectively, these factors are positioning lentiviral gene therapy as a promising field in the next generation of advanced therapeutics.

• For instance, in February 2025, Boehringer Ingelheim International GmbH, launched a Phase I/II trial of BI 3720931, a novel, lentiviral gene therapy aiming to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease.

Furthermore, strategic activities such as research and development initiatives, collaborations, mergers, and acquisitions of key companies are anticipated to drive the growth of the market over the coming years.

Lentiviral Gene Therapies Market Driver

Rising Prevalence of Genetic Disorders to Drive Market Growth

The increasing prevalence of genetic and inherited disorders such as β-thalassemia, sickle cell disease, and Metachromatic Leukodystrophy (MLD) is creating a strong demand for curative gene therapies. Lentiviral vectors offer permanent gene correction through stable integration, making them ideal for lifelong disease management. Recent approvals by the regulatory bodies have demonstrated their clinical effectiveness for genetic diseases. As diagnosis rates and awareness rise globally, the adoption of lentiviral gene therapies is expected to accelerate significantly in the near future.

• For instance, in August 2025, World Health Organization (WHO) published a report which estimated that 7.73 million people were suffering from sickle cell anemia in 2021. Such high prevalence is expected to lead to high patient volume in need of effective gene therapies. Such factors are poised to drive the market growth.

Download Free sample to learn more about this report.

According to data published by Cell & Gene Therapy in April 2021, lentivirus therapies is emerging as a promising field in the gene therapy marketspace.

Lentiviral Gene Therapies Market Restraint

High Prices along with Reimbursement Challenges to Hamper Product Adoption

The high manufacturing and treatment costs of lentiviral gene therapies act as a major market restraint. The production of these therapies involve complex vector manufacturing, cell manipulation, and long quality-control processes, driving per-patient costs. Such pricing limits accessibility, especially in low- and middle-income regions, and poses challenges for reimbursement. As a result, despite strong clinical efficacy, the economic burden hinders large-scale adoption and market penetration.

• For example, in April 2024, WTWH Media LLC., reported the wholesale acquisition cost of Libmeldy, to be around USD 4.25 million. Similarly, the gene therapies Zynteglo and Skysona were priced at USD 2.8 million and USD 3.0 million per dose, respectively. Such high prices are likely to hamper the adoption of these novel lentiviral gene therapies.

Lentiviral Gene Therapies Market Opportunity

Increasing Partnerships with CDMOs for Scalable Manufacturing to Offer Lucrative Growth Opportunities

The demand for large-scale production of lentiviral gene therapies is creating new opportunities for partnerships with specialized manufacturing companies. Many biotechnology firms lack the advanced facilities needed to produce these complex vectors. Working with specialized manufacturers helps improve efficiency, quality, and reliability in production. Such collaborations make it easier to meet the growing market needs and support the wider availability of gene therapies.

• For instance, in October 2025, OXB acquired a cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc. (Resilience). This is aimed to meet the rising demand of such targeted gene therapies. Such factors offer new growth avenues for market players.

Segmentation

Key Insights

The report covers the following key insights:

• Regulatory Scenarios, By Key Countries/Regions
• Overview of Technological Advancements in the Lentiviral Gene Therapies
• New Product Launches, By Key Players
• Pipeline Analysis, By Key Companies
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
• Investment & Funding Trends in the Market

Analysis by Product

On the basis of product, the global lentiviral gene therapies market is segmented into Skysona, Lyfgenia, Zynteglo, Libmeldy, and others.

Among these, the Skysona segment is expected to hold a leading market share. The high segmental share is due to its ability to provide a functional cure for sickle cell disease, one of the most prevalent genetic disorders worldwide. The large patient population and limited curative alternatives, such as bone marrow transplants, strengthen its adoption potential. Moreover, rising healthcare investment and improved access programs for genetic therapies are expected to accelerate Lyfgenia’s market penetration. Furthermore, early approval to the gene therapy has supported in the commercialization of this product.

• For Instance, in September 2022, Genetix Biotherapeutics received approval form the U.S. FDA for Skysona to slow the progression of the neurodegenerative dysfunction in early, active cerebral adrenoleukodystrophy (CALD) in boys aged 4-17 years.

Analysis by Delivery Method

On the basis of delivery method, the market is classified into ex-vivo and in-vivo.

Among these delivery methods, the ex-vivo segment is projected to dominate the market over the forecast period. The segment constitutes the vast majority of approved and late-stage clinical products contributing toward the segment’s dominance. This type of delivery also ensures high safety and low immunogenicity. Due to these advantages, various key companies are collaborating to manufacture these therapies and commercialize them.

• For instance, in January 2025, AGC Biologics in collaboration with Adaptimmune launched lentiviral vector commercial manufacturing for Lete-Cel Product.

These factors are expected to drive the segmental growth.

Analysis by Disease Indication

Based on disease indication, the market is segmented into Β-Thalassemia, Cerebral Adrenoleukodystrophy (CALD), Sickle Cell Disease, and others.

The sickle cell disease segment is expected to generate a significant revenue share in the global lentiviral gene therapies market. The dominance of the segment is due to strong clinical validation, large patient prevalence, and successful commercial approvals of lentiviral gene therapy for sickle cell anemia.

• For instance, in May 2024, CDC reported Sickle Cell Disease (SCD) affects about 100,000 people in the U.S. Such high rates are poised to drive the growth of the segment.

Analysis by End User

In terms of end users, the market is categorized into hospitals & clinics, specialty clinics, and others.

The hospitals & clinics segment is expected to hold a significant share in the global lentiviral gene therapies market. Hospitals and specialty clinics play a central role in the delivery of these therapies to the patients. These hospital settings are equipped with the infrastructure for complex procedures required for therapy administration. To meet the increasing demand, various CDMOs are further enhancing their vector manufacturing capabilities, driving the segmental growth.

• For instance, in November 2023, the Great Ormond Street Hospital for Children received new MHRA authorization to manufacture viral vectors. Such developments are poised to drive the segmental growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, has been studied across North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America.

North America accounted for around 60% share of the global lentiviral gene therapies market in 2024. The dominance of the region is due to high biotechnology ecosystem, advanced healthcare infrastructure, and high R&D investment in gene and cell therapies. The high prevalence of genetic and hematologic disorders also drives therapy adoption. Growing reimbursement initiatives and early patient access programs further strengthen North America’s position as the global hub for lentiviral gene therapy research and commercialization. These advantages reinforce the high market share of the region and propel growth.

• For example, Child Neurology Foundation reported that about 1 in 20,000 males are born with cerebral ALD in the U.S. Such high incidence of genetic disorders is anticipated to augment the demand and drive the market growth in the region.

The Europe market is expected to grow at a significant CAGR over the forecast period due to rising number of investment and funding opportunities in the region along with supportive government regulatory framework and health systems that support reimbursement for rare disease therapies. The region’s combination of innovation-friendly policy, manufacturing infrastructure, and early commercialization experience is fueling sustained market growth. Furthermore, considering the rising demand, many key companies are focusing on the expansion of manufacturing capabilities.

• For instance, in December 2024, VIVEbiotech secured growth investment from Ampersand Capital Partners to expand lentiviral vector development and manufacturing capabilities.

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The region is anticipated to witness growth due to increasing government investment, emerging biotech ecosystems, and growing clinical trial activity.

• For instance, in October 2024, Celaid Therapeutics received an investment of USD 0.92 million in from KUC1 Investment Limited Partnership and Techno Science Co., Ltd. Additionally, the rising demand for affordable therapies and collaborations between Asian biotech’s and Western CDMOs are expected to improve regional access.

Key Players covered

The global lentiviral gene therapies market is consolidated with a few players capturing a major market player.

The report includes the profiles of the following key players.

• ELIXI International SA (Switzerland)
• Stevenage Bioscience Catalyst (U.K.)
• VIVEbiotech (Spain)
• Oxford Biomedica (U.K.)
• Miltenyi Biotec (Germany)
• Genetix Biotherapeutics (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Orchard Therapeutics plc (U.K.)

Key Industry Developments

• October 2024: Orchard Therapeutics partnered with Er-Kim to broaden access to Libmeldy to eligible patients in Turkey and certain Eurasian countries. Libmeldy is indicated for children with early-onset metachromatic leukodystrophy (MLD).
• August 2022: Genetix Biotherapeutics previously known as bluebird bio, Inc. received approval from the U.S. FDA for ZYNTEGLO (betibeglogene autotemcel), also known as beti-cel, to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.